

## Network Life Sciences comments on CNN's news story, "Ebola crisis..."

**Vancouver, B.C., November 23, 2015** – Network Life Sciences Inc. ("Network", "the Company") commented on a news article written by CNN titled, "Ebola crisis: WHO slammed by Harvard-convened panel over slow response". According to Ashish K. Jha of Harvard Global Health Institute, "The most egregious failure was by the World Health Organization ("WHO") in the delay in sounding the alarm"... "people at the WHO were aware that there was an Ebola outbreak" by spring and waited until August to declare an emergency. According to the article over 11,000 people died from the spread of the disease and no doubt that early detection would have helped stop the spread of the disease. (Read the article here <http://www.cnn.com/2015/11/23/africa/ebola-lancet-report/index.html> ).

Network Life Sciences is dedicated to helping in the early detection of the Ebola virus. On June 12, the Company announced the acquisition of an exclusive worldwide license to an Ebola Virus detection kit technology. The Ebola Test Kit technology works on a proprietary immunofiltration platform and provides results, using only fingerstick blood samples, producing accurate results in 60 seconds. See the entire news release <http://www.networklifesciencesinc.com/investors/>.

The Ebola Test Kit technology developed by privately held biolytical Laboratories Inc., ("biolytical") has the potential to help in the treatment of the disease. "There is a very short time window for the accurate detection of the Ebola virus in an infected individual before it's too late and the patient succumbs to the rapid progression of the disease. bioLytical's innovative, new assay detects very low levels of the Ebola virus which is critical to early diagnosis and furthermore provides results in as little as 60 seconds," said Rick Galli, Chief Technical Officer of bioLytical. "A 60 second test is a game-changer, allowing for the masses to be screened quickly and efficiently in remote areas and at airports, seaports and other points of entry."

**About bioLytical Laboratories:** bioLytical Laboratories Inc. is a privately owned Canadian company engaged in the research, development and commercialization of rapid, point-of-care in vitro medical diagnostics using its proprietary INSTITM technology platform with a concentration on HIV. Today, the company markets and sells its signature INSTITM HIV test and has a world- wide footprint of regulatory approvals including U.S. FDA approval, Health Canada approval and CE mark from European regulators. bioLytical has an active R&D program and their pipeline includes INSTITM tests for diseases such as Hepatitis C and Ebola. For more information on bioLytical Laboratories, please visit [www.biolytical.com](http://www.biolytical.com).

**About Network Life Sciences Inc.:** Network has acquired a core portfolio of oncology generic products for the European markets with possible expansion to other territories, as well as pursuing the commercialization for future sale of an Ebola testing kit designed for field use. The Company is commercially focused and is dedicated to serving the oncology and disease testing marketplaces by understanding local market dynamics and its customers unmet needs. The Company has the ability to identify and pursue profitable segments of the oncology market in conjunction with providing value-added products and support services for its portfolio.

### Further Information

Further details are available under the Company's profile on SEDAR at [www.sedar.com](http://www.sedar.com), and the Company's profile on the CSE's website at [www.cnsx.ca](http://www.cnsx.ca).

For further information please contact:

Bill Thomas, CFO, and Director

Telephone: 604 649-5245

E-mail: [info@networkoncology.com](mailto:info@networkoncology.com)

Website: [www.networkoncology.com](http://www.networkoncology.com)

Canadian Securities Exchange (CSE): Symbol NOI

Deutsche Boerse Xetra - Frankfurt Stock Exchange: Symbol 2NY; WKN#: A11827

**Forward-Looking Information:** This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of the Company. Forward-looking information is based on certain key expectations and assumptions made by the management of the Company including future plans for the development and sale of oncological pharmaceutical products and the ebola testing technology. Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release and the Company disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the Canadian Securities Exchange and other risks detailed from time to time in the filings made by the Company with securities regulators.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.